ELMWOOD PARK, N.J.,
July 20, 2020 /PRNewswire/
-- BioReference Laboratories, Inc., an OPKO Health company
(NASDAQ: OPK), today announced it will accept an Indefinite
Delivery Indefinite Quantity (IDIQ) contract award to provide
Commercial Surge Capacity Testing for COVID-19 Emergency Response
to the Centers for Disease Control and Prevention (CDC).
Under the contract with the CDC, BioReference will perform
antibody testing to determine COVID-19 seroprevalence, and will
provide results with key demographic information and analysis in
collaboration with the CDC. The agreement's period of performance
began July 20, 2020, and is ongoing
through November 19, 2020.
"Working with the CDC underscores the importance of public,
private partnership to achieve a worthwhile COVID-19 response,"
said Jon R. Cohen, M.D., Executive Chairman of BioReference
Laboratories. "Many studies suggest that the majority of the public
has not been infected with COVID-19, but multiple factors limit
these findings. Together with the leading public health authority,
we are leveraging extensive depth and breadth of testing expertise
to increase overall understanding of the disease burden of the
virus."
For more information,
visit https://www.bioreference.com/coronavirus.
About BioReference Laboratories, Inc.
BioReference provides comprehensive testing to physicians, clinics,
hospitals, employers, government units, correctional institutions
and medical groups. The company is in network with the five largest
health plans in the United
States, operates a network of 11 laboratory locations, and
is backed by a medical staff of more than 120 MD, PhD and other
professional level clinicians and scientists. For more information,
visit www.bioreference.com.
About OPKO Health
OPKO Health, Inc., is a
multinational biopharmaceutical and diagnostics company that seeks
to establish industry leading positions in large, rapidly growing
markets by leveraging its discovery, development and
commercialization expertise and novel and proprietary technologies.
For more information, visit www.opko.com.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains "forward-looking statements," as
that term is defined under the Private Securities Litigation Reform
Act of 1995 (PSLRA), which statements may be identified by words
such as "expects," "plans," "projects," "will," "may,"
"anticipates," "believes," "should," "intends," "estimates," and
other words of similar meaning, including statements regarding
BioReference's testing for COVID-19, the benefits of the contract
with the CDC, the timing of and availability of the test, the
expected daily capacity for testing, and the actual demand for our
test, as well as other non-historical statements about our
expectations, beliefs or intentions regarding our business,
technologies and products, financial condition, strategies or
prospects. Many factors could cause our actual activities or
results to differ materially from the activities and results
anticipated in forward-looking statements. These factors include
those described in the OPKO Health, Inc. Annual Reports on Form
10-K filed and to be filed with the Securities and Exchange
Commission and in its other filings with the Securities and
Exchange Commission. In addition, forward-looking statements may
also be adversely affected by equipment and reagent shortages,
general market factors, competitive product development, product
availability, federal and state regulations and legislation, the
regulatory process for new products and indications, manufacturing
issues that may arise, patent positions and litigation, among other
factors. The forward-looking statements contained in this press
release speak only as of the date the statements were made, and we
do not undertake any obligation to update forward-looking
statements. We intend that all forward-looking statements be
subject to the safe-harbor provisions of the PSLRA
View original content to download
multimedia:http://www.prnewswire.com/news-releases/opko-healths-bioreference-laboratories-awarded-commercial-surge-capacity-testing-for-covid-19-emergency-response-contract-by-centers-for-disease-control-and-prevention-cdc-301096374.html
SOURCE BioReference Laboratories, Inc